7ZWB
human Carbonic Anhydrase II in complex with 4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)thio)benzenesulfonamide
This is a non-PDB format compatible entry.
Summary for 7ZWB
| Entry DOI | 10.2210/pdb7zwb/pdb |
| Descriptor | Carbonic anhydrase 2, ZINC ION, 4-[(2~{S},3~{R},4~{S},5~{S},6~{R})-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]sulfanylbenzenesulfonamide, ... (4 entities in total) |
| Functional Keywords | carbonic anhydrase, inhibitor, metalloenzyme, sulfonamide, glucose, lyase |
| Biological source | Homo sapiens (human) |
| Total number of polymer chains | 1 |
| Total formula weight | 30057.26 |
| Authors | Angeli, A.,Ferraroni, M. (deposition date: 2022-05-19, release date: 2023-05-31, Last modification date: 2024-06-12) |
| Primary citation | Angeli, A.,Ferraroni, M.,Granchi, C.,Minutolo, F.,Chen, X.,Shriwas, P.,Russo, E.,Leo, A.,Selleri, S.,Carta, F.,Supuran, C.T. First-in-Class Dual Targeting Compounds for the Management of Seizures in Glucose Transporter Type 1 Deficiency Syndrome. J.Med.Chem., 66:10010-10026, 2023 Cited by PubMed Abstract: The genetic disorder glucose transporter type 1 deficiency syndrome (GLUT1-DS) heavily affects the main intake of energy in tissues and determines the most relevant outcomes at the central nervous system (CNS) district, which is highly dependent on glucose. Herein, we report the design and development of a set of compounds bearing the glucosyl and galactosyl moieties. We assessed their ability to enhance the GLUT1 mediated glucose intake in non-small-cell lung cancer (NSCLC) cells and to inhibit the carbonic anhydrase (CA; EC 4.2.1.1) isoforms implicated in the physiopathology of uncontrolled seizures associated to epilepsy (i.e., I, II, IV, VA, VB, and XII). The binding mode of in adduct with hCA II was determined by X-ray crystallography. Among the selected derivatives, compound proved effective in suppressing the occurrence of uncontrolled seizures on the induced maximal electroshock (MES) model and thus gives sustainment of an unprecedently reported pharmacological approach for the management of GLUT1-DS associated diseases. PubMed: 37436184DOI: 10.1021/acs.jmedchem.3c00938 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (1.48 Å) |
Structure validation
Download full validation report
